PetVivo Continues Expansion of IP Assets With Canadian Patent Grant

MINNEAPOLIS, MN / ACCESSWIRE / September 21, 2015 / PetVivo Holdings, Inc. (PINKSHEETS: PETV) an emerging biomedical device company focused on the commercialization of innovative medical devices for pets or pet therapeutics is pleased to announce the grant of Canadian Patent Number 2,583,561 titled “Biocompatible Protein Particles, Particle Devices and Methods Thereof.” PetVivo’s intellectual property assets have now grown to twenty patents.

This Canadian patent includes sixty-six claims, which secure a wide range of protein-based materials, medical devices and pharmaceutical delivery devices in addition to the therapeutic treatments that utilize these devices. Here is a brief overview of some of the assets secured by this patent:

– Biocompatible medical devices that include protein materials designed to mimic the host tissue in composition and/or promote the remodeling of the particle devices into an architectural framework that supports natural tissue growth. The protein material used to produce the devices can be optimized to provide desired characteristics, such as durability, elasticity, strength and drug elution control.

– Therapeutic treatments that utilize this protein material include wound healing, tissue repair, tissue fillers, tissue replacements and tissue grafts.

– These protein materials can also be utilized for the preparation of drug delivery devices for the controlled release of pharmacologically active agents that are homogenously dispersed throughout each protein particle.

– Utilizing these biocompatible protein materials for coating and encapsulating medical devices for various applications including, stents, tubular grafts, vascular grafts, meshes, skin/bone/tissue grafts, adhesion prevention barriers, cell scaffolding and other biocompatible implants.

“We are pleased to see the ongoing expansion of the intellectual property related to our devices. This expansion highlights the novelty of our many protein based materials and devices,” commented PetVivo CEO John Lai, “We continue to show that our protein particles improve the quality of life for dogs and horses suffering from osteoarthritis. We are seeing success beyond twelve months after a single treatment of the Kush(TM) particles.”

To treat lameness a licensed veterinarian injects the Kush particles into the affected joints. Kush’s soft, resilient particles work by providing a protective cushion to the joint where its natural cartilage is missing or damaged. These particles are formulated to provide the mechanical support required to absorb the forces found in an articulating joint.

“Our biocompatible particle technology continues to gain broader patent protection for our many device and pharmaceutical delivery applications.” noted PetVivo’s CTO, Dr. David B. Masters, “Our Kush Canine particles continually demonstrate the functionality of cartilage by providing a slippery cushion of micro-sponges to the joint that helps to alleviate pain and provide protection to halt the progression of further damage, which can also allow native reparative mechanisms to work at healing the afflicted joints.”

PetVivo’s research estimates that osteoarthritis and lameness currently impacts twenty million dogs and one million horses in the United States and Europe. The Kush devices are part of a portfolio of more than seventeen therapeutic candidates in various stages of development for both veterinary and human clinical applications.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to acquire or in-license proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.

For more information, visit: www.PetVivo.com.

Forward-Looking Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

John Lai
Chief Executive Officer
PetVivo Holdings, Inc.
Email: info@petvivo.com
Phone: 612-296-7305

SOURCE: PetVivo Holdings, Inc.

ReleaseID: 432116